<DOC>
	<DOCNO>NCT00085306</DOCNO>
	<brief_summary>RATIONALE : Interferon beta may interfere growth tumor cell . PURPOSE : This phase II trial study well interferon beta work treat patient metastatic cutaneous ( skin ) melanoma ocular ( eye ) melanoma .</brief_summary>
	<brief_title>Interferon Beta Treating Patients With Metastatic Cutaneous Melanoma Ocular Melanoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine objective clinical response rate patient metastatic cutaneous ocular melanoma treat interferon beta . - Determine frequency degree apoptosis induction patient treat drug . - Determine safety tolerability drug patient . OUTLINE : This open-label study . Patients stratify accord type melanoma ( ocular vs cutaneous ) . Patients receive interferon beta subcutaneously daily absence disease progression unacceptable toxicity . Patients follow within 3 day completion study treatment survival . PROJECTED ACCRUAL : A total 28-56 patient ( 14-28 per stratum ) accrue study .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic melanoma Cutaneous ocular disease Measurable disease No active unstable CNS metastases neurologic exam AND CT scan MRI Irradiated and/or resect CNS lesion allow evidence disease head MRI CT scan &gt; 6 month surgery and/or radiotherapy Patients cutaneous metastasis previously irradiate and/or resect CNS metastasis eligible CNS metastasis control require dexamethasone PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 01 ( 02 patient cutaneous metastasis ) Life expectancy At least 3 month Hematopoietic Absolute neutrophil count ≥ 1,200/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.5 g/dL Hepatic Bilirubin ≤ 1.5 mg/dL AST ≤ 3.0 time normal Alkaline phosphatase ≤ 2.5 time normal ( 10 time normal due bone metastasis ) Hepatitis B surface antigen negative Renal Creatinine ≤ 1.5 mg/dL Cardiovascular No serious cardiac arrhythmia require treatment No congestive heart failure No angina pectoris No New York Heart Association class IIIV heart disease No severe cardiovascular disease Other HIV negative No malignancy within past 3 year except basal cell squamous cell skin cancer carcinoma situ uterine cervix No history seizure disorder No severe psychiatric disorder Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy More 12 month since prior adjuvant interferon alfa2 ( IFNα2 ) therapy More 30 day since prior IFNα2 therapy metastatic disease ( 6 month patient cutaneous metastasis ) No 1 prior systemic regimen ( chemotherapy biologic ) metastatic disease ( 3 regimen patient cutaneous metastasis ) Chemotherapy See Biologic therapy No concurrent chemotherapy Endocrine therapy See Disease Characteristics Concurrent replacement therapy physiologic dose corticosteroid allow No concurrent dexamethasone steroidal antiemetic antiinflammatories No concurrent hormonal agent except steroid administer preexist adrenal failure hormone administer nondiseaserelated condition ( e.g. , insulin diabetes ) Radiotherapy See Disease Characteristics More 28 day since prior radiotherapy recover No concurrent palliative radiotherapy Surgery See Disease Characteristics No prior organ allograft More 28 day since prior major surgery require general anesthesia Other More 28 day since prior antibiotic local systemic infection No concurrent aspirin No concurrent barbiturates No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>recurrent melanoma</keyword>
	<keyword>stage IV melanoma</keyword>
	<keyword>iris melanoma</keyword>
	<keyword>ciliary body choroid melanoma , medium/large size</keyword>
	<keyword>extraocular extension melanoma</keyword>
	<keyword>recurrent intraocular melanoma</keyword>
</DOC>